- 19 April 2018
1:00 pm - 2:00 pm
Thursday 19 APRIL 2018, 1.00 PM
Auditorium, Level 6, Bancroft Building
Adoptive cell therapy: Population coverage, potency and new targets
Dr Corey Smith,
Translational and Human Immunology,
QIMR Berghofer Medical Research Institute
Adoptive T cell therapy works through the T cell mediated recognition of peptide epitopes presented by particular HLA class I or II molecules on the surface of infected cells or cancer cells. Due to the genetic diversity of HLA molecules in the human population and the binding of different peptides to different HLA molecules, optimal population coverage is dependent upon the identification of peptide epitopes that can be recognised by T cells on a broad range of HLA molecules. While this approach has not been used heavily to treat non-viral cancers, it is now a standard approach for the development of patient-derived or allogeneic off-the-shelf approaches to treat viral associated complications and cancers. Here I will describe an adoptive cell therapy approach we designed for a first-in-human study treating cytomegalovirus-associated complications in patients who have undergone a solid organ transplant and discuss our studies investigating what impacts upon the potential potency of these T cell therapies. I will also discuss new strategies for the development of adoptive cell therapies targeting non-viral antigens.
Dr Corey Smith completed his PhD in 2004 in the Microbiology and Immunology Department at the University of Melbourne. He then joined Professor Rajiv Khanna’s Tumour Immunology Laboratory, where his work focused on the immune control of common human viral infections associated with cancer and disease in transplant settings, and in translation of these observations into new adoptive cell therapy approaches. In 2017, Dr Smith was promoted to a Team Head position at QIMR Berghofer, and now leads the Translational and Human Immunology Group.